{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:37:31Z","timestamp":1787020651910,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["1RO1NS079637"],"award-info":[{"award-number":["1RO1NS079637"]}]},{"name":"NIH","award":["1RO1NS097722"],"award-info":[{"award-number":["1RO1NS097722"]}]},{"name":"NIH","award":["F31NS092202"],"award-info":[{"award-number":["F31NS092202"]}]},{"name":"NIH","award":["5T32GM118292"],"award-info":[{"award-number":["5T32GM118292"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vascular contributions to cognitive impairment and dementia (VCID) are the second leading cause of dementia behind only Alzheimer\u2019s disease (AD); however, VCID is commonly found as a co-morbidity with sporadic AD. We have previously established a mouse model of VCID by inducing hyperhomocysteinemia in both wild-type and amyloid depositing mice. While we have shown the time course of neuropathological events in the wild-type mice with hyperhomocysteinemia, the effect of amyloid deposition on this time course remains unknown; therefore, in this study, we determined the time course of neuropathological changes in our mouse model of hyperhomocysteinemia-induced VCID in amyloid depositing mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>APP\/PS1 mice were placed on either a diet deficient in folate and vitamins B6 and B12 and enriched in methionine to induce hyperhomocysteinemia or a control diet for 2, 6, 10, 14, or 18\u2009weeks. Immunohistochemistry and gene expression analysis were used to determine neuroinflammatory changes. Microhemorrhages and amyloid deposition were analyzed using histology and, finally, behavior was assessed using the 2-day radial arm water maze.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neuroinflammation, specifically a pro-inflammatory phenotype, was the first pathological change to occur. Specifically, we see a significant increase in gene expression of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, and interleukin 12a by 6\u2009weeks. This was followed by cognitive deficits starting at 10\u2009weeks. Finally, there is a significant increase in the number of microhemorrhages at 14\u2009weeks on diet as well as redistribution of amyloid from the parenchyma to the vasculature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The time course of these pathologies points to neuroinflammation as the initial, key player in homocysteine-induced VCID co-morbid with amyloid deposition and provides a possible therapeutic target and time points.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-019-1685-z","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T12:02:44Z","timestamp":1577707364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Time course of neuropathological events in hyperhomocysteinemic amyloid depositing mice reveals early neuroinflammatory changes that precede amyloid changes and cerebrovascular events"],"prefix":"10.1186","volume":"16","author":[{"given":"Erica M.","family":"Weekman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany L.","family":"Sudduth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittani R.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail E.","family":"Woolums","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Seaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-1564","authenticated-orcid":false,"given":"Donna M.","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"issue":"3","key":"1685_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13311-011-0047-z","volume":"8","author":"DA Levine","year":"2011","unstructured":"Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics. 2011;8(3):361\u201373.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"1685_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jalz.2014.10.008","volume":"11","author":"HM Snyder","year":"2015","unstructured":"Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(6):710\u20137.","journal-title":"Alzheimers Dement"},{"key":"1685_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev.med.49.1.31","volume":"49","author":"H Refsum","year":"1998","unstructured":"Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31\u201362.","journal-title":"Annu Rev Med"},{"issue":"11","key":"1685_CR4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/archneur.55.11.1449","volume":"55","author":"R Clarke","year":"1998","unstructured":"Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55(11):1449\u201355.","journal-title":"Arch Neurol"},{"key":"1685_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1186\/1471-2458-14-643","volume":"14","author":"MA Beydoun","year":"2014","unstructured":"Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;14:643.","journal-title":"BMC Public Health"},{"issue":"1","key":"1685_CR6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gps.2303","volume":"25","author":"A Oulhaj","year":"2010","unstructured":"Oulhaj A, Refsum H, Beaumont H, Williams J, King E, Jacoby R, et al. Homocysteine as a predictor of cognitive decline in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2010;25(1):82\u201390.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"7","key":"1685_CR7","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.neurobiolaging.2014.01.013","volume":"35","author":"YM Choe","year":"2014","unstructured":"Choe YM, Sohn BK, Choi HJ, Byun MS, Seo EH, Han JY, et al. Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden. Neurobiol Aging. 2014;35(7):1519\u201325.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"1685_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/archneur.59.5.787","volume":"59","author":"E Hogervorst","year":"2002","unstructured":"Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol. 2002;59(5):787\u201393.","journal-title":"Arch Neurol"},{"issue":"8","key":"1685_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/WNR.0b013e328346bf85","volume":"22","author":"P Rajagopalan","year":"2011","unstructured":"Rajagopalan P, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM. Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport. 2011;22(8):391\u20135.","journal-title":"Neuroreport"},{"issue":"9","key":"1685_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000000168","volume":"82","author":"RP Kloppenborg","year":"2014","unstructured":"Kloppenborg RP, Geerlings MI, Visseren FL, Mali WP, Vermeulen M, van der Graaf Y, et al. Homocysteine and progression of generalized small-vessel disease: the SMART-MR study. Neurology. 2014;82(9):777\u201383.","journal-title":"Neurology"},{"issue":"Pt 9","key":"1685_CR11","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1093\/brain\/awt206","volume":"136","author":"B Hooshmand","year":"2013","unstructured":"Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, et al. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain. 2013;136(Pt 9):2707\u201316.","journal-title":"Brain"},{"issue":"2","key":"1685_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jnnp.2008.149286","volume":"80","author":"LM de Lau","year":"2009","unstructured":"de Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM. Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry. 2009;80(2):149\u201357.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1685_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pscychresns.2005.09.003","volume":"140","author":"DV Iosifescu","year":"2005","unstructured":"Iosifescu DV, Papakostas GI, Lyoo IK, Lee HK, Renshaw PF, Alpert JE, et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (part I). Psychiatry Res. 2005;140(3):291\u20139.","journal-title":"Psychiatry Res"},{"issue":"6","key":"1685_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00019442-200411000-00009","volume":"12","author":"TM Scott","year":"2004","unstructured":"Scott TM, Tucker KL, Bhadelia A, Benjamin B, Patz S, Bhadelia R, et al. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry. 2004;12(6):631\u20138.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3613","key":"1685_CR15","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1126\/science.143.3613.1443","volume":"143","author":"SH Mudd","year":"1964","unstructured":"Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an enzymatic defect. Science. 1964;143(3613):1443\u20135.","journal-title":"Science"},{"issue":"5","key":"1685_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/jcbfm.2013.1","volume":"33","author":"TL Sudduth","year":"2013","unstructured":"Sudduth TL, Powell DK, Smith CD, Greenstein A, Wilcock DM. Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J Cereb Blood Flow Metab. 2013;33(5):708\u201315.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1685_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2016.11.024","volume":"341","author":"TL Sudduth","year":"2017","unstructured":"Sudduth TL, Weekman EM, Price BR, Gooch JL, Woolums A, Norris CM, et al. Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID). Neuroscience. 2017;341:42\u201351.","journal-title":"Neuroscience"},{"issue":"3","key":"1685_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/alzrt262","volume":"6","author":"TL Sudduth","year":"2014","unstructured":"Sudduth TL, Weekman EM, Brothers HM, Braun K, Wilcock DM. beta-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP\/PS1 transgenic mice. Alzheimers Res Ther. 2014;6(3):32.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1685_CR19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/nprot.2006.275","volume":"1","author":"J Alamed","year":"2006","unstructured":"Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1(4):1671\u20139.","journal-title":"Nat Protoc"},{"issue":"7","key":"1685_CR20","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1523\/JNEUROSCI.5066-07.2008","volume":"28","author":"DM Wilcock","year":"2008","unstructured":"Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, et al. Progression of amyloid pathology to Alzheimer\u2019s disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci. 2008;28(7):1537\u201345.","journal-title":"J Neurosci"},{"issue":"2","key":"1685_CR21","doi-asserted-by":"publisher","first-page":"e31993","DOI":"10.1371\/journal.pone.0031993","volume":"7","author":"TL Sudduth","year":"2012","unstructured":"Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM. Lithium treatment of APPSwDI\/NOS2\u2212\/\u2212 mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One. 2012;7(2):e31993.","journal-title":"PLoS One"},{"issue":"3","key":"1685_CR22","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/nprot.2006.277","volume":"1","author":"DM Wilcock","year":"2006","unstructured":"Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc. 2006;1(3):1591\u20135.","journal-title":"Nat Protoc"},{"issue":"1","key":"1685_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1742-2094-1-24","volume":"1","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1(1):24.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"1685_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"1","key":"1685_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jnnp.64.1.18","volume":"64","author":"JV Bowler","year":"1998","unstructured":"Bowler JV, Munoz DG, Merskey H, Hachinski V. Fallacies in the pathological confirmation of the diagnosis of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 1998;64(1):18\u201324.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"1685_CR26","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1001\/jama.2012.3556","volume":"307","author":"BD James","year":"2012","unstructured":"James BD, Bennett DA, Boyle PA, Leurgans S, Schneider JA. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA. 2012;307(17):1798\u2013800.","journal-title":"JAMA"},{"issue":"23","key":"1685_CR27","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1001\/jama.292.23.2901","volume":"292","author":"KM Langa","year":"2004","unstructured":"Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 2004;292(23):2901\u20138.","journal-title":"JAMA"},{"issue":"8","key":"1685_CR28","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1046\/j.1532-5415.2002.50367.x","volume":"50","author":"D Zekry","year":"2002","unstructured":"Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002;50(8):1431\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"1685_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","volume":"9","author":"GL Semenza","year":"2014","unstructured":"Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47\u201371.","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"1685_CR30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1073\/pnas.75.3.1554","volume":"75","author":"W Cammer","year":"1978","unstructured":"Cammer W, Bloom BR, Norton WT, Gordon S. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination. Proc Natl Acad Sci U S A. 1978;75(3):1554\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1685_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/CS20160604","volume":"131","author":"GA Rosenberg","year":"2017","unstructured":"Rosenberg GA. Extracellular matrix inflammation in vascular cognitive impairment and dementia. Clin Sci (Lond). 2017;131(6):425\u201337.","journal-title":"Clin Sci (Lond)"},{"issue":"7","key":"1685_CR32","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1523\/JNEUROSCI.22-07-02451.2002","volume":"22","author":"FJ Sim","year":"2002","unstructured":"Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci. 2002;22(7):2451\u20139.","journal-title":"J Neurosci"},{"issue":"1","key":"1685_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1161\/01.RES.75.1.181","volume":"75","author":"ZS Galis","year":"1994","unstructured":"Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75(1):181\u20139.","journal-title":"Circ Res"},{"issue":"2","key":"1685_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9","volume":"61","author":"GG Vecil","year":"2000","unstructured":"Vecil GG, Larsen PH, Corley SM, Herx LM, Besson A, Goodyer CG, et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res. 2000;61(2):212\u201324.","journal-title":"J Neurosci Res"},{"issue":"4","key":"1685_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.jcbfm.9600375","volume":"27","author":"Y Yang","year":"2007","unstructured":"Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27(4):697\u2013709.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1685_CR36","volume-title":"Homocystinuria caused by cystathionine beta-synthase deficiency","author":"SJ Sacharow","year":"1993","unstructured":"Sacharow SJ, Picker JD, Levy HL. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, et al., editors. Homocystinuria caused by cystathionine beta-synthase deficiency. Seattle: GeneReviews((R)); 1993."},{"issue":"38","key":"1685_CR37","doi-asserted-by":"publisher","first-page":"9896","DOI":"10.1523\/JNEUROSCI.1762-16.2016","volume":"36","author":"EM Weekman","year":"2016","unstructured":"Weekman EM, Sudduth TL, Caverly CN, Kopper TJ, Phillips OW, Powell DK, et al. Reduced efficacy of anti-Abeta immunotherapy in a mouse model of amyloid deposition and vascular cognitive impairment comorbidity. J Neurosci. 2016;36(38):9896\u2013907.","journal-title":"J Neurosci"},{"issue":"22","key":"1685_CR38","doi-asserted-by":"publisher","first-page":"16036","DOI":"10.1074\/jbc.M700641200","volume":"282","author":"P Michaluk","year":"2007","unstructured":"Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, et al. Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem. 2007;282(22):16036\u201341.","journal-title":"J Biol Chem"},{"issue":"12","key":"1685_CR39","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1111\/j.1460-9568.2011.07688.x","volume":"33","author":"S Noell","year":"2011","unstructured":"Noell S, Wolburg-Buchholz K, Mack AF, Beedle AM, Satz JS, Campbell KP, et al. Evidence for a role of dystroglycan regulating the membrane architecture of astroglial endfeet. Eur J Neurosci. 2011;33(12):2179\u201386.","journal-title":"Eur J Neurosci"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1685-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1685-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1685-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T06:15:19Z","timestamp":1722233719000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1685-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1685-z","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"9 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}